Cohance Lifesciences Ltd
(NSE:COHANCE)
₹
455.95
+6.05 (+1.34%)
Market Cap: 174.56 Bil
Enterprise Value: 176.59 Bil
PE Ratio: 165.07
PB Ratio: 4.41
GF Score: 82/100 
Q1 2027 Cohance Lifesciences Ltd Earnings Call Transcript
Aug 05, 2026 / 01:00PM GMT
Release Date Price:
₹429.45
(+1.07%)
Key Points
Positve
- Cohance Lifesciences Ltd (BOM:543064) secured a significant restocking order for a commercial molecule, providing meaningful delivery visibility for Q4 FY27 and FY28.
- The company's customized ADC payload order remains on schedule for Q2 delivery, and shipments for an oligonucleotide program commenced in Q1, supporting revenue visibility.
- Cohance Lifesciences Ltd (BOM:543064) completed multiple customer audits across its pharma CDMO and API sites without any critical findings, reinforcing customer confidence.
- The company is making strategic progress in its nucleic acid business, with Seppala reporting 2.5 times revenue growth in Q1 and a clear path to full ownership by FY30.
- Cohance Lifesciences Ltd (BOM:543064) achieved external recognition, including EcoVadis Gold, strong CBP ratings, and SBTI validation, highlighting its commitment to sustainability and quality.
- The API business remained resilient, performing slightly ahead of internal expectations with favorable pricing and an improved product mix, supported by a robust order book.
- The company is expanding its ADC portfolio with new products like MMAE and Excitant, which are gaining traction as alternatives to Chinese suppliers.
- Cohance Lifesciences Ltd (BOM:543064) is progressing on its growth agenda, with two molecules moving into commercial supply and a Phase 2 program expanding from KSM to API supply.
- The company's balance sheet remains resilient with consolidated net cash of approximately $2,512 million as of June 30, 2026.
- Cohance Lifesciences Ltd (BOM:543064) is investing in future capabilities, including a commercial flow reactor and new GMP manufacturing laboratory at NJ Bio, to support long-term growth.
Negative
- Cohance Lifesciences Ltd (BOM:543064) reported a 23% year-on-year decline in consolidated revenue for Q1 FY27, with pharma CDMO revenue down 38.7% due to shipment phasing.
- Adjusted EBITDA margin fell to 2.2% in Q1, reflecting lower revenue base, negative operating leverage, and the impact of subsidiary consolidation.
- NJ Bio's performance weighed significantly on consolidated profitability, reporting an adjusted EBITDA loss of $328 million and lower-than-expected revenue.
- The specialty chemicals segment declined 34.7% year-on-year in Q1, primarily due to expected H2-dominated phasing of products in AgChem CDMO.
- The formulation business performed below expectations, impacted by an API production delay, lower demand for a mature product, and a customer-led change in pack configuration.
- The company received a Form 483 with five observations from the USFDA following an inspection of its Pasha Milan facility, though none related to data integrity.
- Cohance Lifesciences Ltd (BOM:543064) faces ongoing challenges at its Nacharam facility, with remediation and operational stabilization remaining an immediate priority.
- The company's $1 billion sales target for FY30 remains uncertain, with management indicating it may be an aspiration rather than a firm commitment.
- Biotech funding environment continues to influence timing of customer decisions, particularly for NJ Bio's FTE program renewals.
- The company expects margin recovery to be weighted towards the second half of the year, with near-term profitability remaining under pressure.
Operator
Ladies and gentlemen, good day and welcome to the Q1 FY27 Earnings Conference Call of Cohan Life Sciences.
(Operator Instructions)
As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity to ask questions after the presentation concludes.
Should you require assistance during the conference, please signal an operator by pressing star followed by zero on your touch tone phone.
Please note that this conference is being recorded.
Before we begin, I would like to remind you that today's discussion may include forward-looking statements that are subject to risks and uncertainties.
Actual results may differ materially from those expressed or implied.
We encourage you to review the disclosures filed by the company.
I now hand the conference over to Ms. Cinderella Carvalho. Over to you, ma'am.
Cyndrella Carvalho
Cohance Lifesciences Limited - Head of Investor Relations
Thank you, Darwin.
Good evening and good morning, everyone.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers